Table 1 Association of clinical characteristics and treatment response with pretreatment serum ApoA1 levels
Parameters | Classification | ApoA1 | P | |
|---|---|---|---|---|
Low (n = 320) | Normal (n = 629) | |||
Age (years)a | > 60 | 114 (35.63%) | 239 (38.00%) | 0.475 |
|  | ≤ 60 | 206 (64.38%) | 390 (62.00%) |  |
Sex | Male | 225 (70.31%) | 349 (55.48%) | < 0.001 |
| Â | Female | 95 (29.69%) | 280 (44.52%) | Â |
B symptoms | Absent | 177 (55.31%) | 546 (86.80%) | < 0.001 |
| Â | Present | 143 (44.69%) | 83 (13.20%) | Â |
LDH | >ULN | 231 (72.19%) | 241 (38.31%) | < 0.001 |
| Â | Normal | 89 (27.81%) | 388 (61.69%) | Â |
ECOG score | 0–1 | 212 (66.25%) | 537 (85.37%) | < 0.001 |
|  | 2–4 | 108 (33.75%) | 92 (14.63%) |  |
Ann Arbor Stage | I–II | 63 (19.69%) | 260 (41.34%) | < 0.001 |
|  | III–IV | 257 (80.31%) | 369 (58.66%) |  |
Extranodal | >1 | 151 (47.19%) | 174 (27.66%) | < 0.001 |
disease | ≤ 1 | 169 (52.81%) | 455 (72.34%) |  |
IPI | Low risk (0–1) | 65 (20.31%) | 291 (46.26%) | < 0.001 |
| Â | Low-intermediate risk (2) | 69 (21.56%) | 144 (22.89%) | Â |
| Â | High-intermediate risk (3) | 100 (31.25%) | 121 (19.24%) | Â |
|  | High risk (4–5) | 86 (26.88%) | 73 (11.61%) |  |
Cell of origin | GCB | 85 (26.56%) | 224 (35.61%) | < 0.001 |
| Â | non-GCB | 206 (64.38%) | 384 (61.05%) | Â |
| Â | Undetermined | 29 (9.06%) | 21 (3.34%) | Â |
Relapse/Refractory | Yes | 120 (37.50%) | 158 (25.12%) | < 0.001 |
| Â | No | 200 (62.50%) | 471 (74.88%) | Â |